Skip to content

SUPerficial ENDometriosis In Magnetic Resonance Imaging

Prospective, Multicenter Study Evaluating the Diagnostic Performance of the 3DT1 Sequence in Magnetic Resonance Imaging for Superficial Endometriosis

Status
Withdrawn
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06195280
Acronym
SUPENDIM
Enrollment
0
Registered
2024-01-08
Start date
2025-04-30
Completion date
2026-03-31
Last updated
2026-01-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Endometriosis

Brief summary

The purpose of the study is to determine the correlation between the diagnosis of Superficial endometriosis by the 3DT1 sequence on Magnetic resonance imaging and the histology obtained by laparoscopy.

Detailed description

This is a prospective, multicenter, non-randomized study evaluating the diagnostic performance of Magnetic Resonance Imaging in superficial endometriosis. The duration of the patient's participation in the study is a maximum of 15 months depending on the length of the screening period and the time between Magnetic Resonance Imaging and laparoscopy. After selection, the investigator will check the patient's eligibility and offer her the study. If she accepts and signs the informed consent form, the patient will have an exploratory pelvic Magnetic Resonance Imaging lasting approximately 15 to 20 minutes, without systematic injection of contrast product. After Magnetic Resonance Imaging, the patient will benefit from a laparoscopy under general anesthesia lasting an average of one hour.

Interventions

RADIATIONMagnetic resonance imaging, 3DT1 sequence

The patient will have an exploration pelvic Magnetic Resonance Imaging lasting approximately 15 to 20 minutes, without systematic injection of contrast product.

PROCEDURELaparoscopy

After Magnetic Resonance Imaging, the patient will benefit from a laparoscopy under general anesthesia lasting an average of one hour.

Sponsors

Euraxi Pharma
CollaboratorINDUSTRY
GCS Ramsay Santé pour l'Enseignement et la Recherche
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Intervention model description

Prospective, multicenter, non-randomized study

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

: * Age ≥ 18 years; * Non-menopausal patient; * Patient scheduled for exploratory laparoscopy; * Patient requiring a preoperative pelvic MRI * Patient having been informed and having signed an informed consent form.

Exclusion criteria

: * Classic contraindications to magnetic resonance imaging; * Contraindications to anesthesia for exploratory laparoscopy; * Contraindication to surgery following the findings of magnetic resonance imaging results; * Patient with endometrioma \> 4 cm; * Patient with known deep endometriosis; * Patient uncooperative with protocol requirements or unable to attend the center for scheduled visits; * Pregnant woman or woman of childbearing age, without effective contraception or breastfeeding; * Patient participating in another clinical trial, or during a period of exclusion from another clinical trial; * Patient under guardianship, under curatorship or subject to legal protection, persons deprived of liberty by a judicial or administrative decision, persons subject to psychiatric care and admitted to a health or social establishment; * Patient not beneficiary of a social security system * Patient under State Medical Aid.

Design outcomes

Primary

MeasureTime frameDescription
Correlation between the diagnosis of superficial endometriosis by the 3DT1 sequence in Magnetic Resonance Imaging and the histology obtained by laparoscopybetween 30 and 150 daysThe diagnostic validity of Magnetic resonance imaging compared to laparoscopy will be determined by correlation between the locations of the sites screened on Magnetic resonance imaging (Douglas cul de sac, vesicouterine cul de sac, right ovarian fossa, left ovarian fossa, right broad ligament, left broad ligament) and histologically confirmed endometriotic implants at these sites.

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026